Biotech Stock Still 700%: What Investors Should Do Today
A biotech stock still 700% has defied gravity, even as it slumps 30% this year. Learn how to read the signals, what a...
We compare the 2024 outlook for index funds and target date funds to help you choose the right retirement path.
23,982 articlesA biotech stock still 700% has defied gravity, even as it slumps 30% this year. Learn how to read the signals, what a...
A leading wealth manager launches a new regional bank holding with $4.5 million in seed capital. Explore what this me...
As shoppers stretch budgets, investors wonder: is walmart stock still safe? This deep dive examines Walmart's defensi...
JEPI has struggled to keep up with a rallying market in 2026, fueling debate over whether its income strategy still f...
As AI data centers push energy use higher, nuclear power is being framed as the only real baseload option. This piece...
Publicly traded crypto firms rose 23% in the first half of 2026 while crypto assets declined 36%, widening the gap to...
As 2026 opens with mixed signals, investors seek ballast. This story examines three dividend ETFs that actually shiel...
When a notable small-cap manager exits a large stake in a data-security firm, it creates questions for investors. Thi...
Electrocore (ECOR) is navigating a pivotal year. This article dives into the 2025 earnings landscape, unpacking reven...
On May 12, 2026, the U.S. welcomed its first spot ETF tied to Hyperliquid's HYPE token. THYP opened on NASDAQ with $1...
Salesforce unveiled a record $25 billion accelerated share repurchase funded by debt as it posted quarterly results. ...
A surge of headlines about aliens and the Catholic Church is reshaping how investors think about religion, charity, a...